Viventia
Founded Year
1995Stage
Acquired | AcquiredValuation
$0000About Viventia
Viventia, fka Novopharm Biotech, is a biopharmaceutical company that designs, develops, engineers, and commercializes protein therapeutic technology and advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer. Viventia is employing its monoclonal antibody discovery and development platforms to discover, validate, and advance a portfolio of new antibody products based on oncology drug targets.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Viventia Patents
Viventia has filed 18 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/11/2016 | 3/10/2020 | Antineoplastic drugs, Experimental cancer drugs, Monoclonal antibodies, Alkylating antineoplastic agents, Orphan drugs | Grant |
Application Date | 3/11/2016 |
|---|---|
Grant Date | 3/10/2020 |
Title | |
Related Topics | Antineoplastic drugs, Experimental cancer drugs, Monoclonal antibodies, Alkylating antineoplastic agents, Orphan drugs |
Status | Grant |
Latest Viventia News
Jan 27, 2017
Viventia Bio Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 19:05 EST 26 Jan 2017 | BioPortfolio Reports Home » Topics » Biotechnology » Latest News » Viventia Bio Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 Summary Viventia Bio Inc Viventia Bio, formerly Viventia Biotechnologies Inc. is a biopharmaceutical company that discovers and develops new generation monoclonal antibody products for patients suffering from cancer. The company's products include VB4845, VB4847, VB6845d and VB7756. Its VB4845 is a recombinant fusion protein, which is designed for the treatment of highgrade nonmuscle invasive bladder cancer. Viventia Bio's VB4847 is a recombinant fusion protein, which is designed for the treatment of latestage squamous cell carcinoma of the head and neck. The company provides immune driven antibody platform to select tumorspecific antibodies with no to minimal normal tissue reactivity using functional assays. Viventia is headquartered in Winnipeg, Manitoba, Canada. Viventia Bio Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Viventia Frequently Asked Questions (FAQ)
When was Viventia founded?
Viventia was founded in 1995.
Where is Viventia's headquarters?
Viventia's headquarters is located at 147 Hamelin Street, Winnipeg.
What is Viventia's latest funding round?
Viventia's latest funding round is Acquired.
Who are the investors of Viventia?
Investors of Viventia include Sesen Bio.
Who are Viventia's competitors?
Competitors of Viventia include Biosceptre International, Celator Pharmaceuticals, Dyax, Artisan Pharma, Syntarga and 14 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Viventia to Competitors
BioSkills is a service company founded to provide its customers with basic and advanced skills in life science and biotech area. BioSkills achieves its primary objectives by developing original formation initiatives in order to spread relevant knowledge base.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins
Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
Therigy is a biopharmaceutical services company focused on improving the use of biotech therapy to achieve healthcare outcomes through the integration of therapy management and technology. Through Therigy's consulting and solutions delivery, clients can achieve optimal clinical results across all distribution channels. Therigy's customers include: health plans, pharmaceutical manufacturers, and pharmacy providers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
